Depression impacts visual function

Article

Depression in retinitis pigmentosa (RP) patients worsens vision-related function even where visual acuity is not compromised, according to a study published in the May 2008 issue of the British Journal of Ophthalmology.

Depression in retinitis pigmentosa (RP) patients worsens vision-related function even where visual acuity is not compromised, according to a study published in the May 2008 issue of the British Journal of Ophthalmology.

Professor H Gon Yu of the Department of Ophthalmology, Seoul National University College of Medicine, Korea and colleagues gave 144 RP patients the National Eye Institute Visual Function Questionnaire (NEI-VFQ) to evaluate vision-related quality of life and the Beck Depression Inventory (BDI) to assess symptoms of depression.

Based on BDI score, patients were categorized into two groups, depressed and non-depressed, and NEI-VFQ composite and subscale scores were compared between groups. The researchers found that, regardless of actual visual acuity or function, depressed patients had worse subjective visual function than non-depressed patients.

The lack of correlation between NEI-VFQ and BDI scores indicated to the researchers that depression has no impact on visual acuity in RP patients but that vision-related functions are decreased in depressed subjects; the researchers concluded that diagnosing and treating depression would improve quality of life for RP patients.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.